The significance of TNFAIP8 in prostate cancer response to radiation and docetaxel and disease recurrence

Chuanbo Zhang, Bhaskar V. Kallakury, Jeffrey S. Ross, Rajshree R. Mewani, Christine E. Sheehan, Isamu Sakabe, George Luta, Deepak Kumar, Sivaramakrishna Yadavalli, Joshua Starr, Taduru L. Sreenath, Shiv Srivastava, Harvey B. Pollard, Ofer Eidelman, Meera Srivastava, Usha N. Kasid

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

TNFAIP8 is a NF-κB-inducible, oncogenic molecule. Previous "promoter array" studies have identified differential methylation and regulation of TNFAIP8 in prostate epithelial and cancer cell lines. Here we demonstrate that TNFAIP8 expression is induced by androgen in hormone-responsive LNCaP prostate cancer cells. In athymic mice bearing hormone-refractory PC-3 prostate tumor xenografts, intravenous treatment with a liposomal formulation of TNFAIP8 antisense oligonucleotide (LE-AS5) caused reduced expression of TNFAIP8 in tumor tissues, and a combination of LE-AS5 and radiation or docetaxel treatment resulted in significant inhibition of PC-3 tumor growth as compared to single agents. The immunohistochemical evaluation of TNFAIP8 expression revealed correlation of both cytoplasmic and nuclear TNFAIP8 overexpression with high grade prostatic adenocarcinomas, while nuclear overexpression was found to be an independent predictor of disease recurrence controlling for tumor grade. Increased nuclear TNFAIP8 expression was statistically significantly associated with a 2.44 fold (95 % confidence interval: 1.01-5.91) higher risk of prostate cancer recurrence. Mechanistically, TNFAIP8 seems to function as a scaffold (or adaptor) protein. In the antibody microarray analysis of proteins associated with the TNFAIP8 immune-complex, we have identified Karyopherin alpha2 as a novel binding partner of nuclear TNFAIP8 in PC-3 cells. The Ingenuity Pathway Analysis of the TNFAIP8 interacting proteins suggested that TNFAIP8 influences cancer progression pathways and networks involving integrins and matrix metalloproteinases. Taken together, present studies demonstrate that TNFAIP8 is a novel therapeutic target in prostate cancer, and indicate a potential relationship of the nuclear trafficking of TNFAIP8 with adverse outcomes in a subset of prostate cancer patients. What's new? TNFAIP8, an NF-κB- inducible protein, is an emerging oncogenic molecule of interest, owing to evidence for its possible role in tumor growth and progression. In this study, the first to investigate the therapeutic significance of TNFAIP8, in vivo TNFAIP8 knockdown was found to enhance the efficacy of radiation and docetaxel in a hormone-refractory prostate tumor xenograft model. Furthermore, nuclear TNFAIP8 overexpression was discovered to be an independent predictor of recurrent prostate cancer. The findings indicate that TNFAIP8 may be a key therapeutic target and prognostic marker for prostate cancer.

Original languageEnglish (US)
Pages (from-to)31-42
Number of pages12
JournalInternational Journal of Cancer
Volume133
Issue number1
DOIs
StatePublished - Jul 2013

Fingerprint

docetaxel
Prostatic Neoplasms
Radiation
Recurrence
Neoplasms
Hormones
Heterografts
Prostate
Therapeutics
Protein Array Analysis
Antisense Oligonucleotides
Growth
Antigen-Antibody Complex
Matrix Metalloproteinases
Nude Mice
Integrins
Methylation
Androgens
Proteins
Adenocarcinoma

Keywords

  • KPNA2
  • prognosis
  • prostate cancer
  • therapy response
  • TNFAIP8

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Zhang, C., Kallakury, B. V., Ross, J. S., Mewani, R. R., Sheehan, C. E., Sakabe, I., ... Kasid, U. N. (2013). The significance of TNFAIP8 in prostate cancer response to radiation and docetaxel and disease recurrence. International Journal of Cancer, 133(1), 31-42. https://doi.org/10.1002/ijc.27996

The significance of TNFAIP8 in prostate cancer response to radiation and docetaxel and disease recurrence. / Zhang, Chuanbo; Kallakury, Bhaskar V.; Ross, Jeffrey S.; Mewani, Rajshree R.; Sheehan, Christine E.; Sakabe, Isamu; Luta, George; Kumar, Deepak; Yadavalli, Sivaramakrishna; Starr, Joshua; Sreenath, Taduru L.; Srivastava, Shiv; Pollard, Harvey B.; Eidelman, Ofer; Srivastava, Meera; Kasid, Usha N.

In: International Journal of Cancer, Vol. 133, No. 1, 07.2013, p. 31-42.

Research output: Contribution to journalArticle

Zhang, C, Kallakury, BV, Ross, JS, Mewani, RR, Sheehan, CE, Sakabe, I, Luta, G, Kumar, D, Yadavalli, S, Starr, J, Sreenath, TL, Srivastava, S, Pollard, HB, Eidelman, O, Srivastava, M & Kasid, UN 2013, 'The significance of TNFAIP8 in prostate cancer response to radiation and docetaxel and disease recurrence', International Journal of Cancer, vol. 133, no. 1, pp. 31-42. https://doi.org/10.1002/ijc.27996
Zhang, Chuanbo ; Kallakury, Bhaskar V. ; Ross, Jeffrey S. ; Mewani, Rajshree R. ; Sheehan, Christine E. ; Sakabe, Isamu ; Luta, George ; Kumar, Deepak ; Yadavalli, Sivaramakrishna ; Starr, Joshua ; Sreenath, Taduru L. ; Srivastava, Shiv ; Pollard, Harvey B. ; Eidelman, Ofer ; Srivastava, Meera ; Kasid, Usha N. / The significance of TNFAIP8 in prostate cancer response to radiation and docetaxel and disease recurrence. In: International Journal of Cancer. 2013 ; Vol. 133, No. 1. pp. 31-42.
@article{80bb01d40ca74677a50da2b0f3e727da,
title = "The significance of TNFAIP8 in prostate cancer response to radiation and docetaxel and disease recurrence",
abstract = "TNFAIP8 is a NF-κB-inducible, oncogenic molecule. Previous {"}promoter array{"} studies have identified differential methylation and regulation of TNFAIP8 in prostate epithelial and cancer cell lines. Here we demonstrate that TNFAIP8 expression is induced by androgen in hormone-responsive LNCaP prostate cancer cells. In athymic mice bearing hormone-refractory PC-3 prostate tumor xenografts, intravenous treatment with a liposomal formulation of TNFAIP8 antisense oligonucleotide (LE-AS5) caused reduced expression of TNFAIP8 in tumor tissues, and a combination of LE-AS5 and radiation or docetaxel treatment resulted in significant inhibition of PC-3 tumor growth as compared to single agents. The immunohistochemical evaluation of TNFAIP8 expression revealed correlation of both cytoplasmic and nuclear TNFAIP8 overexpression with high grade prostatic adenocarcinomas, while nuclear overexpression was found to be an independent predictor of disease recurrence controlling for tumor grade. Increased nuclear TNFAIP8 expression was statistically significantly associated with a 2.44 fold (95 {\%} confidence interval: 1.01-5.91) higher risk of prostate cancer recurrence. Mechanistically, TNFAIP8 seems to function as a scaffold (or adaptor) protein. In the antibody microarray analysis of proteins associated with the TNFAIP8 immune-complex, we have identified Karyopherin alpha2 as a novel binding partner of nuclear TNFAIP8 in PC-3 cells. The Ingenuity Pathway Analysis of the TNFAIP8 interacting proteins suggested that TNFAIP8 influences cancer progression pathways and networks involving integrins and matrix metalloproteinases. Taken together, present studies demonstrate that TNFAIP8 is a novel therapeutic target in prostate cancer, and indicate a potential relationship of the nuclear trafficking of TNFAIP8 with adverse outcomes in a subset of prostate cancer patients. What's new? TNFAIP8, an NF-κB- inducible protein, is an emerging oncogenic molecule of interest, owing to evidence for its possible role in tumor growth and progression. In this study, the first to investigate the therapeutic significance of TNFAIP8, in vivo TNFAIP8 knockdown was found to enhance the efficacy of radiation and docetaxel in a hormone-refractory prostate tumor xenograft model. Furthermore, nuclear TNFAIP8 overexpression was discovered to be an independent predictor of recurrent prostate cancer. The findings indicate that TNFAIP8 may be a key therapeutic target and prognostic marker for prostate cancer.",
keywords = "KPNA2, prognosis, prostate cancer, therapy response, TNFAIP8",
author = "Chuanbo Zhang and Kallakury, {Bhaskar V.} and Ross, {Jeffrey S.} and Mewani, {Rajshree R.} and Sheehan, {Christine E.} and Isamu Sakabe and George Luta and Deepak Kumar and Sivaramakrishna Yadavalli and Joshua Starr and Sreenath, {Taduru L.} and Shiv Srivastava and Pollard, {Harvey B.} and Ofer Eidelman and Meera Srivastava and Kasid, {Usha N.}",
year = "2013",
month = "7",
doi = "10.1002/ijc.27996",
language = "English (US)",
volume = "133",
pages = "31--42",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - The significance of TNFAIP8 in prostate cancer response to radiation and docetaxel and disease recurrence

AU - Zhang, Chuanbo

AU - Kallakury, Bhaskar V.

AU - Ross, Jeffrey S.

AU - Mewani, Rajshree R.

AU - Sheehan, Christine E.

AU - Sakabe, Isamu

AU - Luta, George

AU - Kumar, Deepak

AU - Yadavalli, Sivaramakrishna

AU - Starr, Joshua

AU - Sreenath, Taduru L.

AU - Srivastava, Shiv

AU - Pollard, Harvey B.

AU - Eidelman, Ofer

AU - Srivastava, Meera

AU - Kasid, Usha N.

PY - 2013/7

Y1 - 2013/7

N2 - TNFAIP8 is a NF-κB-inducible, oncogenic molecule. Previous "promoter array" studies have identified differential methylation and regulation of TNFAIP8 in prostate epithelial and cancer cell lines. Here we demonstrate that TNFAIP8 expression is induced by androgen in hormone-responsive LNCaP prostate cancer cells. In athymic mice bearing hormone-refractory PC-3 prostate tumor xenografts, intravenous treatment with a liposomal formulation of TNFAIP8 antisense oligonucleotide (LE-AS5) caused reduced expression of TNFAIP8 in tumor tissues, and a combination of LE-AS5 and radiation or docetaxel treatment resulted in significant inhibition of PC-3 tumor growth as compared to single agents. The immunohistochemical evaluation of TNFAIP8 expression revealed correlation of both cytoplasmic and nuclear TNFAIP8 overexpression with high grade prostatic adenocarcinomas, while nuclear overexpression was found to be an independent predictor of disease recurrence controlling for tumor grade. Increased nuclear TNFAIP8 expression was statistically significantly associated with a 2.44 fold (95 % confidence interval: 1.01-5.91) higher risk of prostate cancer recurrence. Mechanistically, TNFAIP8 seems to function as a scaffold (or adaptor) protein. In the antibody microarray analysis of proteins associated with the TNFAIP8 immune-complex, we have identified Karyopherin alpha2 as a novel binding partner of nuclear TNFAIP8 in PC-3 cells. The Ingenuity Pathway Analysis of the TNFAIP8 interacting proteins suggested that TNFAIP8 influences cancer progression pathways and networks involving integrins and matrix metalloproteinases. Taken together, present studies demonstrate that TNFAIP8 is a novel therapeutic target in prostate cancer, and indicate a potential relationship of the nuclear trafficking of TNFAIP8 with adverse outcomes in a subset of prostate cancer patients. What's new? TNFAIP8, an NF-κB- inducible protein, is an emerging oncogenic molecule of interest, owing to evidence for its possible role in tumor growth and progression. In this study, the first to investigate the therapeutic significance of TNFAIP8, in vivo TNFAIP8 knockdown was found to enhance the efficacy of radiation and docetaxel in a hormone-refractory prostate tumor xenograft model. Furthermore, nuclear TNFAIP8 overexpression was discovered to be an independent predictor of recurrent prostate cancer. The findings indicate that TNFAIP8 may be a key therapeutic target and prognostic marker for prostate cancer.

AB - TNFAIP8 is a NF-κB-inducible, oncogenic molecule. Previous "promoter array" studies have identified differential methylation and regulation of TNFAIP8 in prostate epithelial and cancer cell lines. Here we demonstrate that TNFAIP8 expression is induced by androgen in hormone-responsive LNCaP prostate cancer cells. In athymic mice bearing hormone-refractory PC-3 prostate tumor xenografts, intravenous treatment with a liposomal formulation of TNFAIP8 antisense oligonucleotide (LE-AS5) caused reduced expression of TNFAIP8 in tumor tissues, and a combination of LE-AS5 and radiation or docetaxel treatment resulted in significant inhibition of PC-3 tumor growth as compared to single agents. The immunohistochemical evaluation of TNFAIP8 expression revealed correlation of both cytoplasmic and nuclear TNFAIP8 overexpression with high grade prostatic adenocarcinomas, while nuclear overexpression was found to be an independent predictor of disease recurrence controlling for tumor grade. Increased nuclear TNFAIP8 expression was statistically significantly associated with a 2.44 fold (95 % confidence interval: 1.01-5.91) higher risk of prostate cancer recurrence. Mechanistically, TNFAIP8 seems to function as a scaffold (or adaptor) protein. In the antibody microarray analysis of proteins associated with the TNFAIP8 immune-complex, we have identified Karyopherin alpha2 as a novel binding partner of nuclear TNFAIP8 in PC-3 cells. The Ingenuity Pathway Analysis of the TNFAIP8 interacting proteins suggested that TNFAIP8 influences cancer progression pathways and networks involving integrins and matrix metalloproteinases. Taken together, present studies demonstrate that TNFAIP8 is a novel therapeutic target in prostate cancer, and indicate a potential relationship of the nuclear trafficking of TNFAIP8 with adverse outcomes in a subset of prostate cancer patients. What's new? TNFAIP8, an NF-κB- inducible protein, is an emerging oncogenic molecule of interest, owing to evidence for its possible role in tumor growth and progression. In this study, the first to investigate the therapeutic significance of TNFAIP8, in vivo TNFAIP8 knockdown was found to enhance the efficacy of radiation and docetaxel in a hormone-refractory prostate tumor xenograft model. Furthermore, nuclear TNFAIP8 overexpression was discovered to be an independent predictor of recurrent prostate cancer. The findings indicate that TNFAIP8 may be a key therapeutic target and prognostic marker for prostate cancer.

KW - KPNA2

KW - prognosis

KW - prostate cancer

KW - therapy response

KW - TNFAIP8

UR - http://www.scopus.com/inward/record.url?scp=84876674956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876674956&partnerID=8YFLogxK

U2 - 10.1002/ijc.27996

DO - 10.1002/ijc.27996

M3 - Article

VL - 133

SP - 31

EP - 42

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 1

ER -